Pharmaceutical Biotechnology
List Price:
$89.99
- Availability: Confirm prior to ordering
- Branding: minimum 50 pieces (add’l costs below)
- Check Freight Rates (branded products only)
Branding Options (v), Availability & Lead Times
- 1-Color Imprint: $2.00 ea.
- Promo-Page Insert: $2.50 ea. (full-color printed, single-sided page)
- Belly-Band Wrap: $2.50 ea. (full-color printed)
- Set-Up Charge: $45 per decoration
- Availability: Product availability changes daily, so please confirm your quantity is available prior to placing an order.
- Branded Products: allow 10 business days from proof approval for production. Branding options may be limited or unavailable based on product design or cover artwork.
- Unbranded Products: allow 3-5 business days for shipping. All Unbranded items receive FREE ground shipping in the US. Inquire for international shipping.
- RETURNS/CANCELLATIONS: All orders, branded or unbranded, are NON-CANCELLABLE and NON-RETURNABLE once a purchase order has been received.
Product Details
Author:
Michael J. Groves
Format:
Paperback
Pages:
428
Publisher:
CRC Press (September 19, 2019)
Language:
English
Audience:
Professional and scholarly
ISBN-13:
9780367392208
Weight:
27.875oz
Dimensions:
6.125" x 9.1875"
File:
TAYLORFRANCIS-TayFran_260121055302376-20260121.xml
Folder:
TAYLORFRANCIS
List Price:
$89.99
Country of Origin:
United States
Case Pack:
1
As low as:
$85.49
Publisher Identifier:
P-CRC
Discount Code:
H
Pub Discount:
30
Imprint:
CRC Press
Overview
Edited by a world-renowned authority, with contributions from experts, this second edition explores the redefinition of the term biotechnology as applied to pharmaceuticals. The book examines the successful evolution of humanized monoclonal antibodies to treat rheumatoid arthritis and other diseases, considers the currently disappointing results of genetic engineering and genomics that have isolated disease-responsible genes without effect, and looks at the market and scientific reasons behind the failure of many biotechnology products to live up to their hype. It contains a discussion of regulatory and compendial issues and concludes with a look at future challenges facing biotechnology.
